Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3003653 | 0.85 | KMT2A (0.46) | POLBKMT2AKDM4EGFERALDH1A1 | |
| SCHEMBL2173054 | 0.83 | GAA (0.41) | POLBKMT2AMEN1 | |
| SCHEMBL2174285 | 0.83 | GAA (0.41) | POLBKMT2AMEN1 | |
| SCHEMBL2174275 | 0.83 | GAA (0.41) | POLBKMT2AMEN1 | |
| SCHEMBL3004818 | 0.80 | TDP1 (0.39) | TDP1KMT2AGFERALDH1A1HSD11B1 | |
| SCHEMBL3005542 | 0.80 | GFER (0.40) | KMT2AGFERALDH1A1MEN1TSHR | |
| SCHEMBL13794593 | 0.80 | ESR2 (0.45) | POLBTDP1KMT2AKDM4EALDH1A1 | |
| SCHEMBL2996862 | 0.80 | MGLL (0.38) | POLBKMT2AALDH1A1MEN1TSHR | |
| SCHEMBL2999639 | 0.79 | ALDH1A1 (0.40) | POLBTDP1KMT2AKDM4EALDH1A1 | |
| SCHEMBL3003865 | 0.79 | L3MBTL1 (0.44) | POLBTDP1KMT2AALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7544705-B2 | Pyrroloimidazole derivatives, their preparation, pharmaceutical composition containing them, and their use as nootropic agents | NEUROTUNE AG (CH) | 2009-06-09 | — | — | US | claimed |
| EP-1608655-B8 | PYRROLOIMIDAZOLE DERIVATIVES, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE AS NOOTROPIC AGENTS | BRANE DISCOVERY SRL IN LIQUIDA (IT) | 2008-10-15 | — | — | EP | claimed |
| EP-1608655-B1 | PYRROLOIMIDAZOLE DERIVATIVES, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE AS NOOTROPIC AGENTS | NIKEM RESEARCH SRL (IT) | 2008-07-16 | — | — | EP | claimed |
| US-20070027137-A1 | Pyrroloimidazole derivatives, their preparation, pharmaceutical composition containing them, and their use as nootropic agents | NEUROTUNE AG (CH) | 2007-02-01 | — | — | US | claimed |
| EP-1608655-A2 | PYRROLOIMIDAZOLE DERIVATIVES, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE AS NOOTROPIC AGENTS | NIKEM RESEARCH S.R.L. (IT) | 2005-12-28 | — | — | EP | claimed |
| WO-2004085438-A2 | PYRROLOIMIDAZOLE DERIVATIVES, THEIR PREPARATION, PHARMACEUTICAL COMPOSITION CONTAINING THEM, AND THEIR USE AS NOOTROPIC AGENTS | NIKEM RESEARCH S.R.L. (IT) | 2004-10-07 | — | — | WO | claimed |
| US-20100173945-A1 | Compounds with nootropic action, their preparation, pharmaceutical compositions containing them, and use thereof | FARINA CARLO | 2010-07-08 | — | — | US | disclosed |
| US-20100173945-A1 | Compounds with nootropic action, their preparation, pharmaceutical compositions containing them, and use thereof | FARINA CARLO | 2010-07-08 | — | — | US | disclosed |
| US-20100173945-A1 | Compounds with nootropic action, their preparation, pharmaceutical compositions containing them, and use thereof | FARINA CARLO | 2010-07-08 | — | — | US | disclosed |
| US-7732473-B2 | Compounds with nootropic action, their preparation, pharmaceutical compositions containing them, and use thereof | NEUROTUNE AG (CH) | 2010-06-08 | — | — | US | disclosed |
| US-7732473-B2 | Compounds with nootropic action, their preparation, pharmaceutical compositions containing them, and use thereof | NEUROTUNE AG (CH) | 2010-06-08 | — | — | US | disclosed |
| US-7732473-B2 | Compounds with nootropic action, their preparation, pharmaceutical compositions containing them, and use thereof | NEUROTUNE AG (CH) | 2010-06-08 | — | — | US | disclosed |
| US-20090163565-A1 | Compounds with nootropic action, their preperation, pharmaceutical compositions containing them, and use thereof | FARINA CARLO | 2009-06-25 | — | — | US | disclosed |
| EP-1608655-B8 | PYRROLOIMIDAZOLE DERIVATIVES, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE AS NOOTROPIC AGENTS | BRANE DISCOVERY SRL IN LIQUIDA (IT) | 2008-10-15 | — | — | EP | disclosed |
| EP-1608655-B1 | PYRROLOIMIDAZOLE DERIVATIVES, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE AS NOOTROPIC AGENTS | NIKEM RESEARCH SRL (IT) | 2008-07-16 | — | — | EP | disclosed |
| US-20070027137-A1 | Pyrroloimidazole derivatives, their preparation, pharmaceutical composition containing them, and their use as nootropic agents | NEUROTUNE AG (CH) | 2007-02-01 | — | — | US | disclosed |
| US-20070027137-A1 | Pyrroloimidazole derivatives, their preparation, pharmaceutical composition containing them, and their use as nootropic agents | NEUROTUNE AG (CH) | 2007-02-01 | — | — | US | disclosed |
| US-20070027137-A1 | Pyrroloimidazole derivatives, their preparation, pharmaceutical composition containing them, and their use as nootropic agents | NEUROTUNE AG (CH) | 2007-02-01 | — | — | US | disclosed |
| EP-1608655-A2 | PYRROLOIMIDAZOLE DERIVATIVES, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE AS NOOTROPIC AGENTS | NIKEM RESEARCH S.R.L. (IT) | 2005-12-28 | — | — | EP | disclosed |
| WO-2004085438-A2 | PYRROLOIMIDAZOLE DERIVATIVES, THEIR PREPARATION, PHARMACEUTICAL COMPOSITION CONTAINING THEM, AND THEIR USE AS NOOTROPIC AGENTS | NIKEM RESEARCH S.R.L. (IT) | 2004-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173945-A1 | Compounds with nootropic action, their preparation, pharmaceutical compositions containing them, and use thereof | GRIN3B, GRIN3A, GRIN1 | POLB 4750/4885TDP1 3533/4885KMT2A 3610/4885 |
| US-20090163565-A1 | Compounds with nootropic action, their preperation, pharmaceutical compositions containing them, and use thereof | OPRL1, GRIN3B, GRIN3A | POLB 4181/4885TDP1 2407/4885KMT2A 4169/4885 |
| US-20070027137-A1 | Pyrroloimidazole derivatives, their preparation, pharmaceutical composition containing them, and their use as nootropic agents | GRIN3A, GRIN1, GRIN3B | POLB 2567/4885TDP1 1894/4885KMT2A 4212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.